Although pretransplant HLA matching of recipients with cadaveric allografts may add modestly to graft survival, most improvements until now and prospects for the future depend on more effective immunosuppression. During the past 6 years cyclosporine and the anti CD-3 mAb OKT3 have increased graft survival by preventing, delaying or diminishing rejection episodes and by reversing them when they occur. Despite their potent immunosuppressive properties both reagents create new clinical problems even as they improve graft survival; cyclosporine compromises renal function via preglomerular arteriolopathy, and the first dose of OKT-3 leads to a range of potentially serious clinical responses attributed in part to activation of T-cells and release of lymphokines and cytokines: IL-2, IFN-gamma and TNFalpha. Clearly more effective and safe immunosuppressive agents are still needed. At present preclinical testing of potentially immunosuppressive mAbs is limited to in vitro assays and trials in primates whose responses may or may not correspond with those of man. We propose to continue our ongoing program of developing clinically relevant anti T-cell mAbs and will also obtain relevant antibodies from Ortho Biotech. After characterizing them in vitro and (when it is developed) in the hu-SCID mouse model described by Thistlethwaite in this proposal, we will proceed directly to clinical pilot studies in renal transplant recipients at The University of Chicago Medical Center after approved by its Investigational Review Board. We will draw on mouse models described by Bluestone and Fitch to determine clinically relevant regimens of mAbs which alone or in combinations might effectively prevent or reverse rejection with minimal side effects from lymphokines or cytokines. We will also seek regimens that minimize induction of human antibody responses to the murine mAbs. As part of our clinical observations in kidney transplant recipients, we will focus on the development of molecular approaches to analyzing the mechanisms involved in transplant rejection and the effect of mAb therapy on the molecular expression lymphokines and rejection episodes. We will look for evidence of these molecules and other cells obtained from lymphoid tissue and the graft itself.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Gajewski, T F; Fallarino, F; Fields, P E et al. (2001) Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol 166:3900-7
Szot, G L; Zhou, P; Rulifson, I et al. (2001) Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice. Am J Transplant 1:38-46
Alegre, M; Fallarino, F; Zhou, P et al. (2001) Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc 33:209-11
Zhou, P; Szot, G L; Guo, Z et al. (2000) Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 165:5580-7
Kulkarni, S; Holman, P O; Kopelan, A et al. (2000) Programmed cell death signaling via cell-surface expression of a single-chain antibody transgene. Transplantation 69:1209-17
Rezai, K A; Semnani, R T; Farrokh-Siar, L et al. (1999) Human fetal retinal pigment epithelial cells induce apoptosis in allogenic T-cells in a Fas ligand and PGE2 independent pathway. Curr Eye Res 18:430-9
van Seventer, G A; Semnani, R T; Palmer, E M et al. (1998) Integrins and T helper cell activation. Transplant Proc 30:4270-4
Smith, J A; Tang, Q; Bluestone, J A (1998) Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 160:4841-9
Fields, P E; Finch, R J; Gray, G S et al. (1998) B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol 161:5268-75
Madrenas, J; Chau, L A; Smith, J et al. (1997) The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med 185:219-29

Showing the most recent 10 out of 41 publications